Can Alnylam’s AMVUTTRA become a first-line treatment force in ATTR-CM?
ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.
Pharma & Biotech
Pharma & Biotech
How Alnylam Pharmaceuticals is using new ACC.26 data to deepen the case for vutrisiran and zilebesiran
See why Alnylam Pharmaceuticals’ new ACC.26 data on vutrisiran and zilebesiran could reshape cardiovascular strategy and market expectations.
Pharma & Biotech
Alnylam Pharmaceuticals taps Tenaya Therapeutics to uncover new cardiovascular RNAi drug targets
Alnylam Pharmaceuticals partners with Tenaya Therapeutics to discover RNAi targets for cardiovascular disease. Read the analysis behind this biotech collaboration.